CLINICAL TRIALS PROFILE FOR MEVACOR

All Clinical Trials for MEVACOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000512 ↗	Familial Atherosclerosis Treatment Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1984-01-01	To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography.
NCT00000512 ↗	Familial Atherosclerosis Treatment Study	Completed	University of Washington	Phase 3	1984-01-01	To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography.
NCT00062556 ↗	Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication	Completed	Kos Pharmaceuticals	Phase 3	2003-01-01	The purpose of this study is to evaluate if Niacin ER/Lovastatin, at two different doses, compared to diet control (this group will receive a tablet containing 50 mg. of immediate-release niacin) is a safe and effective medicine in subjects with leg pain caused by a narrowing of their leg arteries, a condition called intermittent claudication. At least 366 subjects with leg pain caused by a narrowing of their leg arteries will participate in this study. Niacin ER/Lovastatin is a combination of two FDA (United States Food and Drug Administration) approved cholesterol modifying medications: Niaspan® (extended-release niacin) and lovastatin, a statin (the same medicine found in Mevacor®). Niacin ER/Lovastatin was approved by the FDA under the name of Advicor® for use in the treatment of elevated cholesterol. The use of Niacin ER/Lovastatin in the treatment of peripheral arterial disease and symptomatic relief of intermittent claudication is considered investigational. An investigational use is one that is not approved by the FDA.
NCT00071266 ↗	The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC	Completed	Kos Pharmaceuticals	Phase 3	2003-10-01	The purpose of this study is to compare the dose response and safety of Niacin ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of their leg arteries. At least 870 subjects, with leg pain caused by a narrowing of their leg arteries will take part in this study. Both Niaspan and lovastatin (Mevacor®) are approved by the United States Food and Drug Administration (FDA) to treat high cholesterol. Niacin ER/Lovastatin (Advicor®), a combination of these two drugs, is also approved by the FDA to treat high cholesterol. The use of Niacin ER/Lovastatin to treat narrowing of leg arteries and relieve "intermittent claudication" (leg pain caused by narrowing of the arteries in the leg) is considered investigational. An investigational use is one that is not approved by the FDA.

Clinical Trial Conditions for MEVACOR

Condition Name

Condition Name for MEVACOR
Intervention	Trials
Healthy	2
Breast Cancer	2
Stroke	2
Peripheral Vascular Disease	2

Condition MeSH

Condition MeSH for MEVACOR
Intervention	Trials
Syndrome	3
Peripheral Vascular Diseases	2
Melanoma	2
Peripheral Arterial Disease	2

Clinical Trial Locations for MEVACOR

Trials by Country

Trials by Country for MEVACOR
Location	Trials
United States	86
Canada	3
Taiwan	2

Trials by US State

Trials by US State for MEVACOR
Location	Trials
California	9
New York	4
Pennsylvania	4
North Carolina	4
Florida	4

Clinical Trial Progress for MEVACOR

Clinical Trial Phase

Clinical Trial Phase for MEVACOR
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for MEVACOR
Clinical Trial Phase	Trials
Completed	17
Terminated	6
Withdrawn	2

Clinical Trial Sponsors for MEVACOR

Sponsor Name

Sponsor Name for MEVACOR
Sponsor	Trials
University of Iowa	3
Kos Pharmaceuticals	2
Mutual Pharmaceutical Company, Inc.	2

Sponsor Type

Sponsor Type for MEVACOR
Sponsor	Trials
Other	26
Industry	8
NIH	5